OncoMatch/Clinical Trials/NCT06674265
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
Is NCT06674265 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Allogenic NK cells infusion for neuroblastoma, recurrent, refractory.
Treatment: Allogenic NK cells infusion — The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma. Is the injection of allogenic nk cells safe in patients with R/R high-risk neuroblastoma? Is the injection of allogenic nk cells effective in patients with R/R high-risk neuroblastoma? We will compare the NK cell administration group with a control group that receives conventional treatment to determine whether the intervention is safe and effective
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroblastoma
Prior therapy
Must have received: multi-drug induction chemotherapy — induction
having received at least 4 cycles of multi-drug induction chemotherapy, and not responding to conventional treatments
Must have received: autologous peripheral blood stem cell transplantation or aggressive therapy
relapse or progression of neuroblastoma after autologous peripheral blood stem cell transplantation or aggressive therapy
Lab requirements
Blood counts
platelet count > 50,000/µl, independent of transfusion (no platelet transfusion within one week). absolute neutrophil count (anc) maximum of 500 per microliter. hemoglobin > 10 grams per deciliter.
Kidney function
creatinine clearance or estimated radioisotope gfr < 70 ml/min/1.73m². plasma creatinine level more than 1.5 times the upper limit of normal based on age/gender.
Liver function
plasma bilirubin level more than 1.5 times the upper limit of normal (uln). sgpt (alt) at least three times the upper limit of normal (a level of 45 units per liter is considered the upper limit of normal).
Cardiac function
shortening fraction < 27% by echo or ejection fraction < 50% by echo or gated radionuclide study.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify